A new injectable known as ATX-101 could soon join the ranks of cosmetics that have been approved by the FDA after an investigation involving Dr. Derek Jones. As a dermatologist in the Los Angeles area, he has served as an investigator on trials leading to the approval of a variety of products, including the facial filler family of Juvéderm®, Juvéderm® Ultra Plus, and Juvéderm® Voluma; dermal filler Belotero®; eyelash enhancer Latisse®; and wrinkle-fighter Xeomin®.
Though dermatologist Dr. Jones presented ATX-101 to the FDA in March of this year, he has been involved in this particular investigative process for quite some time. He acted as principal investigator for an ATX-101 study in 2012, pitting the new cosmetic against a placebo in trials aimed at reducing what is clinically termed “localized subcutaneous fat in the submental area.”
ATX-101 manufacturer Kythera reported that double chins are a bothersome problem for seven out of 10 consumers in the United States. More than eight years ago, to combat that problem, scientists began developing a treatment making use of deoxycholic acid to disrupt fat cells and reduce the appearance of fat in the targeted under-chin area without surgery. The process has involved 19 clinical studies and more than 2,600 patients.
If and when ATX-101 is finally approved, patients seeking a solution to their double chins could avoid liposuction and instead see a dermatologist.
To find out more about ATX-101 and how it may be coming to a dermatologist in Los Angeles, contact Dr. Derek Jones and his staff at Skin Care and Laser Physicians of Beverly Hills. Dermatology is their focus. Call 310-246-0495, or request a consultation via the website at skincareandlaser.com.Written by Dr. Derek Jones
Dr. Derek Jones is a renowned Los Angeles and Beverly Hills area dermatologist practicing in cosmetic and general dermatology.